



## Outcomes Survey

### Santa Barbara Dermatology Meeting 2022

#### 1. Please rate the following aspects of this activity.

(1=Strongly Disagree, 2=Disagree, 3=Undecided, 4=Agree, 5=Strongly Agree, 6=N/A)

	Strongly Disagree				N/A	
Attending this activity improved my competence. [9-3.89]	(2) 22.22%	(0)	(0)	(2) 22.22%	(5) 55.56%	(0)
Attending this activity improved my performance. [9-3.89]	(2) 22.22%	(0)	(0)	(2) 22.22%	(5) 55.56%	(0)
What I learned from this activity has helped me improve my patient outcomes. [9-3.78]	(2) 22.22%	(0)	(0)	(3) 33.33%	(4) 44.44%	(0)

#### 2. If this activity improved your competence, please tell us how. (8)

Realizing how not as necessary to classify better or find cause of "red itchy bump disease" with biopsy of spongiotic dermatitis, just necessary to reassure patient that we "can get you back" to normal. Learned list to rule out first other causes by doing labs to rule out hepatitis (hepatic panel), CBC, CMP, anti-giardia, G<sup>+</sup>PD transglutaminase.

Knowledge of new medications

Education in new treatments for Hailey Hailey, urticaria, and EGFR skin reactions has updated my fund of knowledge

Better recognition of chemotherapies affects on the skin. Better knowledge of chemoprevention for skin cancer

Better at filler injections and choices

Knowing when to refer

New info broadened my clinical acumen.

Increased understanding of the JAK and TYK inhibitors.

#### 3. If this activity improved your performance, please tell us how. (7)

If above ruled out labs, then may treat with dapsons with treatment ladder of Dapsone, 25mg titrating up to 200mg, 500mg mycophenolate mofetil titrating up to maximum 1.5g bid, adding low dose prednisone 5-10mg daily and non-sedating antihistamine such as levocetirizine.

Better treatments kess commin conditions

see above

Same as a above filler injections improved with live demo

More Dermatopathology referrals

Application of this info will improve performance.

Becoming more knowledgeable about the JAK and TYK inhibitors will allow me to better take care of patients with atopic dermatitis and psoriasis.

**4. Discuss how your Patient Outcomes (omit patient names) have improved as a result of attending this activity. (7)**

Patients have improved significantly and are less worried about a diagnosis and have new confidence; they have stopped their continuous shopping for a diagnosis with other dermatologists.

N/A

I am using different topical regimens for skin cancer that has improved results with less time involved

Better choice location of fillers

Will increase gene analysis

Better performance will lead to improved pt outcomes.

Potentially better outcomes for treating atopic dermatitis, alopecia areata, and managing high risk squamous cell carcinoma patients.

**5. Identify practice changes you have made as a result of attending this activity. (7)**

Instituted the above protocol as learned above at the conference.

N/A retired

I have been treating more patients with 5FU-calcipotriene combination

see above

More dermatology gene analysis

Expanded tx armamentarium for HS. Improved understanding of tx options for psoriasis and eczema will lead to Rx new meds.

Increased use of calcipotriene in combination with 5-FU for AK's and SCC's. More comfortable using JAK inhibitors.

**6. What topics do you want to hear more about, and what issue(s) in your practice will this help address? (8)**

Other treatment ladders useful for empiric treatment of spongiotic dermatitis-atopic dermatitis when the antigenic drivers cannot be identified and both the patient and dermatologist are frustrated.

Common clinical entities more & less of rare

Treatment of itch, melanoma and update on blistering disorders

The conference always offers good topics and lectures covering a wide variety of subjects thus creating a nice well balanced program.

More on best practices running an office

dermatology, pathology, and surgery

General medical dermatology is my focus.

Work up and treatment of dermal hypersensitivity reactions.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.